ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Hayward Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – HAYW
NEW YORK, Aug. 21, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Hayward Holdings, Inc. (NYSE: HAYW) between
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Eos Energy Enterprises, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – EOSE, EOSEW
NEW YORK, Aug. 21, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Eos Energy Enterprises, Inc. (NASDAQ: EOSE, EOSEW)
ROSEN, TOP RANKED GLOBAL INVESTOR COUNSEL, Encourages Applied Digital Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – APLD
NEW YORK, Aug. 21, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Applied Digital Corporation (NASDAQ: APLD) between
INVNT.ATOM™ Launches BZAR™ a Patent Pending, Interactive Platform Redefining Virtual Commerce, Immersive Engagement, and Community Building for Brands and Fans
Singapore, Aug. 21, 2023 (GLOBE NEWSWIRE) — INVNT.ATOM™, the digital and Web3 innovation division of [INVNT GROUP] THE GLOBAL BRANDSTORY PROJECT™ introduces BZAR™, the GROUP’s patent-pending, self-funded, content-led digital platform,
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Syneos Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SYNH
NEW YORK, Aug. 21, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Syneos Health, Inc. (NASDAQ: SYNH) between September
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ALDX
NEW YORK, Aug. 21, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between March